Name | Ubamatamab |
---|
Description | Ubamatamab (REGN4018) is a human bispecific antibody targeted against Mucin 16 (MUC16) and CD3. Ubamatamab demonstrates potent antitumor activity[1]. |
---|---|
Related Catalog | |
In Vitro | Ubamatamab(REGN4018;0.1 pM-10 nM;48 小时)诱导人 T 细胞和猕猴 T 细胞杀死 OVCAR-3 细胞 (EC50 值分别为 13.6 pM 和 30.6 pM)[1]。 Cell Viability Assay[1] Cell Line: OVCAR-3 cells Concentration: 0.1 pM-10 nM Incubation Time: 48 hours Result: Induced human T cells and cynomolgus T cells to kill OVCAR-3 cells. |
In Vivo | Ubamatamab(REGN4018;0.01-0.5 mg/kg;腹腔注射;第 6、10、13、16 和 21 天)有效抑制腹膜内卵巢肿瘤的生长[1]。 Ubamatamab(REGN4018;0.01-1 mg/kg;i.p;每周一次;总共五剂)显示血清细胞因子和 C 反应蛋白有轻微和短暂的增加,没有明显的毒性[1]。 Animal Model: NOD SCID gamma (NSG) mice injected with OVCAR-3/Luc cells[1] Dosage: 0.01 mg/kg, 0.1 mg/kg, 0.5 mg/kg Administration: i.p; on days 6, 10, 13, 16, and 21 Result: Significantly reduced tumor burden, and did not result in any changes in weight. Animal Model: Cynomolgus monkeys Dosage: 0.01, 0.1, or 1 mg/kg Administration: i.p; once a week; total of five doses Result: Showed minimal and transient increases in serum cytokines and C-reactive protein. |
References |
No Any Chemical & Physical Properties |